bd 1047 has been researched along with Facial Pain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roh, DH; Yoon, SY | 1 |
| Kang, SY; Kim, HC; Kim, HW; Roh, DH; Yoon, SY | 1 |
2 other study(ies) available for bd 1047 and Facial Pain
| Article | Year |
|---|---|
Sigma-1 receptor antagonist, BD1047 reduces nociceptive responses and phosphorylation of p38 MAPK in mice orofacial formalin model.
Topics: Analgesics; Animals; Disease Models, Animal; Ethylenediamines; Facial Pain; Formaldehyde; Lip; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, sigma; Sigma-1 Receptor; Signal Transduction | 2014 |
Clonidine Reduces Nociceptive Responses in Mouse Orofacial Formalin Model: Potentiation by Sigma-1 Receptor Antagonist BD1047 without Impaired Motor Coordination.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Animals; Blood Pressure; Clonidine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Ethylenediamines; Facial Pain; Formaldehyde; Male; Mice, Inbred C57BL; Pain Measurement; Psychomotor Performance; Receptors, sigma; Rotarod Performance Test; Sigma-1 Receptor | 2015 |